A Study of CS1001 in Subjects With Esophageal Squamous Cell Carcinoma
Status:
Recruiting
Trial end date:
2023-12-30
Target enrollment:
Participant gender:
Summary
Phase III Study to Investigate the Efficacy and Safety of CS1001 or Placebo in Combination
with FP as First-Line Therapy in Subjects with Unresectable Locally Advanced, Recurrent or
Metastatic Esophageal Squamous Cell Carcinoma